SXTC China SXT Pharmaceuticals, Inc. Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1723980 · Fiscal year ends 03/31
Financial factors as of 2026-03-31 (FY2026), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-34.6%
TTM net income YoY-87.8%
TTM EPS YoY97.4%
Revenue 3-yr CAGR-16.7%
Net income 3-yr CAGR—
Margins
Gross margin21.9%
Operating margin-625.9%
Net margin-545.2%
FCF margin—
EBITDA margin-619.4%
Returns
ROE-27.5%
ROA-22.0%
ROIC (approx.)—
Asset turnover0.04x
Leverage & solvency
Liabilities / assets14.5%
Debt / equity0.03x
Current ratio7.93x
Interest coverage-113.13x
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-7.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 | FY20242024-03-31 | FY20232023-03-31 | FY20222022-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.14M | $1.74M | $1.93M | $1.97M | $2.60M |
| Cost of revenue | $889,350 | $1.37M | $1.37M | $1.55M | $1.35M |
| Gross profit | $248,702 | $367,427 | $553,971 | $426,271 | $1.25M |
| R&D expense | — | — | $184,194 | $200,717 | $367,005 |
| SG&A expense | $7.13M | $2.76M | $2.64M | $5.65M | $5.52M |
| Operating income | -$7.12M | -$2.68M | -$2.52M | -$5.61M | -$5.19M |
| Interest expense | $62,965 | $648,221 | $544,279 | $476,776 | $36,695 |
| Pretax income | -$6.21M | -$3.30M | -$3.10M | -$5.93M | -$5.41M |
| Income tax | — | — | — | — | $328,146 |
| Net income | -$6.21M | -$3.30M | -$3.10M | -$5.93M | -$5.74M |
| EBITDA | -$7.05M | -$2.60M | -$2.31M | -$5.36M | -$4.87M |
| EPS (basic) | -9.13 | -348.17 | -4,285.66 | -177.84 | -137.92 |
| EPS (diluted) | -9.13 | -348.17 | -4,285.66 | -177.84 | -137.92 |
| Weighted avg. shares (diluted) | 679,648 | 9,489 | 723 | 33,372 | 41,591 |
| Banking | |||||
| Loans, net | — | — | — | $38,358 | $11,404 |
| Deposits | — | $7.27M | — | — | — |
| Balance sheet | |||||
| Cash & equivalents | $28.18M | $18.10M | $12.08M | $17.37M | $15.57M |
| Receivables | $931,567 | $1.30M | $1.31M | $1.34M | $3.33M |
| Inventory | $777,059 | $828,053 | $794,855 | $531,254 | $1.02M |
| Current assets | $34.51M | $21.30M | $14.23M | $19.52M | $22.45M |
| PP&E, net | $117,103 | $178,561 | $328,845 | $962,214 | $1.23M |
| Intangibles | $6,328 | $11,808 | $19,101 | $27,868 | $38,762 |
| Total assets | $34.75M | $21.66M | $23.13M | $29.55M | $33.55M |
| Current liabilities | $4.35M | $6.01M | $8.90M | $14.50M | $17.12M |
| Short-term debt | $355,175 | $8,781 | $21,329 | $7,863 | $11,404 |
| Long-term debt | $644,390 | $96,264 | $117,129 | $117,862 | — |
| Total debt | $999,565 | $105,045 | $138,458 | $125,725 | — |
| Total liabilities | $5.05M | $6.22M | $9.20M | $14.86M | $17.12M |
| Shareholders' equity | $29.71M | $15.44M | $13.93M | $14.69M | $16.08M |
| Net debt | -$27.18M | -$17.99M | -$11.94M | -$17.24M | — |
| Shares outstanding | — | 91,756 | 13.76M | 457,365 | 2.03M |
| Cash flow statement | |||||
| Operating cash flow | -$4.02M | -$2.35M | -$1.93M | -$80,757 | $268,293 |
| Capital expenditure | — | $2,023 | $7,063 | — | — |
| Free cash flow | — | -$2.35M | -$1.94M | — | — |
| Investing cash flow | -$1.25M | $63,516 | $26,423 | -$12,303 | -$46,909 |
| Financing cash flow | $14.43M | $8.40M | -$2.62M | $2.94M | $1.60M |
| Depreciation & amortization | $73,668 | $82,297 | $203,247 | $250,162 | $320,007 |
| Stock-based compensation | $5.31M | — | $352,100 | $554,571 | $2.33M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.